GlassScriptPhysician profile
Phuong Tran
NPI 1275990111
$26,571.33
in general payments reported to CMS, 2019-2025
34 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9,637 · 2022: $6,145 · 2023: $6,423 · 2024: $3,979 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,983 · Food and Beverage: $3,325 · Travel and Lodging: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,982.50 |
| Food and Beverage | $3,325.21 |
| Travel and Lodging | $481.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $11,968.19 | 2021-2024 | Jornay Pm |
| Abbvie INC. | $7,420.93 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,439.30 | 2021-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $949.66 | 2021-2023 | Austedo, Austedo Xr |
| Allergan, INC. | $825.00 | 2021 | |
| Alkermes, INC. | $715.85 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $433.95 | 2021-2024 | Rexulti, Nuedexta, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $415.17 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $328.24 | 2022-2023 | Qelbree |
| Sunovion Pharmaceuticals INC. | $292.31 | 2021-2022 | |
| Eisai INC. | $263.39 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $224.17 | 2021-2024 | Caplyta |
| Lundbeck LLC | $185.83 | 2021-2023 | Rexulti |
| Adlon Therapeutics L.P. | $185.01 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $141.38 | 2021-2024 | Trintellix |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $133.40 | 2022 | |
| Sumitomo Pharma America, INC. | $81.06 | 2023 | Latuda |
| Bausch Health US, LLC | $79.54 | 2021-2025 | Aplenzin, Wellbutrin |
| Indivior INC. | $59.20 | 2021-2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $57.66 | 2021 | |
| Alpha Cognition USA, INC. | $51.71 | 2025 | Zunveyl |
| Axsome Therapeutics, INC. | $36.99 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $36.11 | 2025 | Lumryz |
| Tris Pharma INC | $35.46 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $34.92 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $34.88 | 2021-2023 | Nuplazid |
| Corium, LLC | $26.24 | 2024-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $24.63 | 2025 | Cobenfy |
| Noven Therapeutics, LLC | $20.38 | 2022 | |
| Boston Scientific Corporation | $19.50 | 2023 | Infinion 16 |
| Alfasigma USA, INC. | $16.58 | 2021 | |
| Vertical Pharmaceuticals, LLC | $13.87 | 2024 | Relexxii |
| Idorsia Pharmaceuticals US INC | $13.02 | 2023 | Quviviq |
| Brainsway USA INC | $7.80 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phuong Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.